Stock Track | Twist Bioscience Plummets 19.53% as Q4 Earnings Miss and Cautious 2026 Outlook Rattle Investors

Stock Track11-14

Shares of Twist Bioscience Corp (NASDAQ: TWST) plummeted 19.53% in Friday's trading session, following the release of its fiscal 2025 fourth-quarter results and 2026 guidance. The synthetic DNA technology company's mixed performance and conservative outlook triggered a significant sell-off among investors.

For the fourth quarter ended September 30, 2025, Twist Bioscience reported a net loss of $0.45 per share, missing the analyst consensus estimate of $0.43 loss per share. This wider-than-expected loss overshadowed the company's revenue beat, which came in at $99.009 million, surpassing expectations of $97.317 million and marking a 16.88% increase from the previous year.

Adding to investor concerns, Twist Bioscience's fiscal 2026 guidance fell short of market expectations. The company forecasts total revenue for fiscal 2026 to be in the range of $425 million to $435 million, compared to the FactSet consensus estimate of $431.9 million. This cautious outlook, combined with the earnings miss, has led investors to reassess the company's growth trajectory and profitability prospects, resulting in the sharp stock price decline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164380625?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 22:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164380625","market":"sg","top_or_hot":-1,"title":"Stock Track | Twist Bioscience Plummets 19.53% as Q4 Earnings Miss and Cautious 2026 Outlook Rattle Investors","media":"Stock Track","content":"<p>Shares of Twist Bioscience Corp (NASDAQ: TWST) plummeted 19.53% in Friday's trading session, following the release of its fiscal 2025 fourth-quarter results and 2026 guidance. The synthetic DNA technology company's mixed performance and conservative outlook triggered a significant sell-off among investors.</p>\n\n<p>For the fourth quarter ended September 30, 2025, Twist Bioscience reported a net loss of $0.45 per share, missing the analyst consensus estimate of $0.43 loss per share. This wider-than-expected loss overshadowed the company's revenue beat, which came in at $99.009 million, surpassing expectations of $97.317 million and marking a 16.88% increase from the previous year.</p>\n\n<p>Adding to investor concerns, Twist Bioscience's fiscal 2026 guidance fell short of market expectations. The company forecasts total revenue for fiscal 2026 to be in the range of $425 million to $435 million, compared to the FactSet consensus estimate of $431.9 million. This cautious outlook, combined with the earnings miss, has led investors to reassess the company's growth trajectory and profitability prospects, resulting in the sharp stock price decline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Twist Bioscience Plummets 19.53% as Q4 Earnings Miss and Cautious 2026 Outlook Rattle Investors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Twist Bioscience Plummets 19.53% as Q4 Earnings Miss and Cautious 2026 Outlook Rattle Investors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-14 22:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Twist Bioscience Corp (NASDAQ: TWST) plummeted 19.53% in Friday's trading session, following the release of its fiscal 2025 fourth-quarter results and 2026 guidance. The synthetic DNA technology company's mixed performance and conservative outlook triggered a significant sell-off among investors.</p>\n\n<p>For the fourth quarter ended September 30, 2025, Twist Bioscience reported a net loss of $0.45 per share, missing the analyst consensus estimate of $0.43 loss per share. This wider-than-expected loss overshadowed the company's revenue beat, which came in at $99.009 million, surpassing expectations of $97.317 million and marking a 16.88% increase from the previous year.</p>\n\n<p>Adding to investor concerns, Twist Bioscience's fiscal 2026 guidance fell short of market expectations. The company forecasts total revenue for fiscal 2026 to be in the range of $425 million to $435 million, compared to the FactSet consensus estimate of $431.9 million. This cautious outlook, combined with the earnings miss, has led investors to reassess the company's growth trajectory and profitability prospects, resulting in the sharp stock price decline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"","article_id":"1164380625","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164380625","pubTimestamp":1763130900,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Twist Bioscience Corp (NASDAQ: TWST) plummeted 19.53% in Friday's trading session, following the release of its fiscal 2025 fourth-quarter results and 2026 guidance. The synthetic DNA...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp"},"translate_title":"股票追踪|Twist Bioscience暴跌19.53%，因第四季度盈利未达预期和谨慎的2026年前景令投资者不安","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"Shares of Twist Bioscience Corp (NASDAQ: TWST) plummeted 19.53% in Friday's trading session, following the release of its fiscal 2025 fourth-quarter results and 2026 guidance. The synthetic DNA technology company's mixed performance and conservative outlook triggered a significant sell-off among investors.\nFor the fourth quarter ended September 30, 2025, Twist Bioscience reported a net loss of $0.45 per share, missing the analyst consensus estimate of $0.43 loss per share. This wider-than-expected loss overshadowed the company's revenue beat, which came in at $99.009 million, surpassing expectations of $97.317 million and marking a 16.88% increase from the previous year.\nAdding to investor concerns, Twist Bioscience's fiscal 2026 guidance fell short of market expectations. The company forecasts total revenue for fiscal 2026 to be in the range of $425 million to $435 million, compared to the FactSet consensus estimate of $431.9 million. This cautious outlook, combined with the earnings miss, has led investors to reassess the company's growth trajectory and profitability prospects, resulting in the sharp stock price decline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164380625","isCrawlerRequest":true}